At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Roloff et al presented findings on outcomes among 76 adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) treated with the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel following its U.S. Food and Drug Administration (FDA) approval in October 2021 (Abstract 7001).
